Cours Foamix Pharmaceuticals Ltd. Nasdaq
Actions
IL0011334385
Produits pharmaceutiques
CA 2024 * | 400 k 362 k | CA 2025 * | 250 k 226 k | Capitalisation | 37,64 M 34,1 M |
---|---|---|---|---|---|
Résultat net 2024 * | -32 M -28,99 M | Résultat net 2025 * | -40 M -36,24 M | VE / CA 2024 * | 94,1 x |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 151 x |
PER 2024 * |
-3,3
x | PER 2025 * |
-3,38
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 88,62% |
Dernier transcript sur Foamix Pharmaceuticals Ltd.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 01/03/20 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 01/03/20 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 10/09/20 |
Steven Basta
BRD | Director/Board Member | 59 | 01/01/15 |
Anthony Bruno
BRD | Director/Board Member | 68 | 01/03/20 |
Varia. 1 janv. | Capi. | |
---|---|---|
+30,38% | 684 Md | |
+26,51% | 568 Md | |
-4,36% | 361 Md | |
+19,30% | 329 Md | |
+3,73% | 284 Md | |
+16,70% | 240 Md | |
+8,78% | 208 Md | |
-7,93% | 200 Md | |
+7,68% | 166 Md |